Related Experiment Videos
Biocharacteristics shared by highly protective vaccines against Marek's disease
Isabel M Gimeno1, Richard L Witter, Henry D Hunt
1USDA-ARS Avian Disease and Oncology Laboratory, East Lansing, MI, USA. igimeno@msu.edu
Avian Pathology : Journal of the W.V.P.A
|December 19, 2003
Summary
Higher protective Marek's disease virus (MDV) vaccines replicate better in vivo and stimulate T cells earlier than lower protective ones. However, no single characteristic fully predicts vaccine efficacy, suggesting multiple protective mechanisms for MDV.
Area of Science:
- Veterinary Virology
- Immunology
- Poultry Disease Control
Background:
- Attenuated serotype 1 Marek's disease virus (MDV) strains exhibit variable protection against Marek's disease.
- Understanding the biocharacteristics linked to vaccine efficacy is crucial for improving poultry health.
Purpose of the Study:
- To identify specific biocharacteristics of serotype 1 MDV strains that correlate with enhanced vaccine protection.
- To compare the in vivo replication and immunological effects of high-protection (HP) versus low-protection (LP) MDV vaccines.
Main Methods:
- Comparative analysis of three pairs of HP and LP MDV vaccines from the same strain.
- Inclusion of two additional highly protective vaccines (RM1 and CVI988/BP5) for broader comparison.
- Assessment of in vivo replication, total T cell counts, T cell lineage expansion (CD45(+)CD3(+), CD4(+)CD8(-), CD4(-)CD8(+)), and MhcI/MhcII antigen expression on T cells.
Main Results:
- HP vaccines demonstrated superior in vivo replication compared to LP vaccines.
- HP vaccines induced significant expansion of total T cells and specific T cell subsets (CD4+ and CD8+).
- HP vaccines markedly increased MhcI and MhcII antigen expression on T cells, indicating enhanced immune stimulation.
- Variability in in vivo replication was observed even among highly protective vaccines (RM1/CVI988/BP5 replicated more than CVI988/648A80).
Conclusions:
- In vivo replication and early T-cell lineage stimulation are key characteristics associated with highly protective MDV vaccines.
- No single biocharacteristic definitively identifies the most protective MDV vaccines, suggesting multifaceted mechanisms of action.
- Further research is needed to fully elucidate the complex interplay of factors contributing to MDV vaccine efficacy.